These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 1398464)

  • 1. SMS 201-995 and thyroid function in acromegaly: acute, intermediate and long-term effects.
    Christensen SE; Weeke J; Kaal A; Harris AG; Orskov H
    Horm Metab Res; 1992 May; 24(5):237-9. PubMed ID: 1398464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Behavior of the pituitary-thyroid axis in acromegalic subjects during prolonged intermittent and pulsatile treatment with octreotide].
    Cuttica CM; Fazzuoli L; Cariola G; Carraro A; Porcella E; Giusti M; Giordano G
    Recenti Prog Med; 1994 Jan; 85(1):7-12. PubMed ID: 8184183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxic elevation in serum GH by hypothalamic releasing hormones predicts GH response to acute SMS 201-995 administration.
    Candrina R
    Recenti Prog Med; 1991 Jan; 82(1):13-6. PubMed ID: 1902962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TSH producing pituitary tumor: biochemical diagnosis and long-term medical management with octreotide.
    Chayen SD; Gross D; Makhoul O; Glaser B
    Horm Metab Res; 1992 Jan; 24(1):34-8. PubMed ID: 1612557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pituitary-thyroid axis in acromegaly.
    Eskildsen PC; Kruse A; Kirkegaard C
    Horm Metab Res; 1988 Dec; 20(12):755-7. PubMed ID: 3146541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid and adrenal function tests in adult male ferrets.
    Heard DJ; Collins B; Chen DL; Coniglario J
    Am J Vet Res; 1990 Jan; 51(1):32-5. PubMed ID: 2154147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperresponse to thyrotropin-releasing hormone accompanying small decreases in serum thyroid hormone concentrations.
    Vagenakis AG; Rapoport B; Azizi F; Portnay GI; Braverman LE; Ingbar SH
    J Clin Invest; 1974 Oct; 54(4):913-8. PubMed ID: 4214837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Peripheral thyroid function and TRH-TSH test in patients with acromegaly].
    Heberling HJ; Heilmann W; Ulrich FE; Schneyer U
    Z Gesamte Inn Med; 1981 Apr; 36(8):306-8. PubMed ID: 6792802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyrotropin-releasing hormone stimulation testing in healthy dogs.
    Evinger JV; Nelson RW; Bottoms GD
    Am J Vet Res; 1985 Jun; 46(6):1323-5. PubMed ID: 3927801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum thyrotropin responses to synthetic thyrotropin-releasing hormone in normal children and hypopituitary patients. A new test to distinguish primary releasing hormone deficiency from primary pituitary hormone deficiency.
    Foley TP; Owings J; Hayford JT; Blizzard RM
    J Clin Invest; 1972 Feb; 51(2):431-7. PubMed ID: 4621544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum thyrotropin response to thyrotropin-releasing hormone and free thyroid hormone indices in patients with familiar thyroxine-binding globulin deficiency.
    Konno N
    Endocrinol Jpn; 1976 Aug; 23(4):313-7. PubMed ID: 828576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repetitive administration of thyrotropin-releasing hormone results in small elevations of serum thyroid hormones and in marked inhibition of thyrotropin response.
    Snyder PJ; Utiger RD
    J Clin Invest; 1973 Sep; 52(9):2305-12. PubMed ID: 4199417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents.
    Wood LC; Ingbar SH
    J Clin Invest; 1979 Nov; 64(5):1429-36. PubMed ID: 91625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroxine, triiodothyronine, and thyrotropin in serum during long-term diphenylhydantoin therapy.
    Liewendahl K; Majuri H
    Scand J Clin Lab Invest; 1976 Mar; 36(2):141-4. PubMed ID: 179126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Trials of acute treatment with SMS 201-995 in acromegalics].
    Santos C; García-Luna PP; Acosta D; Pumar A; Pereira JL; Gavilán I; Cuberta F; García de Pesquera F; Astorga R
    Rev Clin Esp; 1991 Jul; 189(3):110-4. PubMed ID: 1947381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum thyrotropin response to thyrotropin-releasing hormone and free thyroid hormone indices in patients with familial thyroxine-binding globulin deficiency.
    Konno N
    Endocrinol Jpn; 1977 Aug; 23(4):313-7. PubMed ID: 72658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and tolerability of octreotide treatment in acromegaly.
    Christensen SE; Weeke J; Orskov H; Kaal A; Lund E; Jørgensen J; Harris AG
    Metabolism; 1992 Sep; 41(9 Suppl 2):44-50. PubMed ID: 1518433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of endotoxin on hormonal responses to thyrotropin and thyrotropin-releasing hormone in dogs.
    Yu AA; Kemppainen RJ; MacDonald JM
    Am J Vet Res; 1998 Feb; 59(2):186-91. PubMed ID: 9492934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.